About vaccines

Researchers performed a large-scale, double-blind, placebo-controlled phase two trial to assess the efficacy, safety, and immune response elicited from vaccination with MVC-COV1901. // 19.10.2021

New tool also reveals numeric differences between vaccines // 19.10.2021

A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%. // 19.10.2021

A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine. // 19.10.2021

The research group reports on the waning effectiveness of the COVID-19 vaccines against transmission to household contacts in the face of these relaxed measures and more transmissible strains of SARS-CoV-2. // 18.10.2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics. // 18.10.2021

To address the gaps in the knowledge, a team of researchers from the University of California and the Gladstone Institute of Virology conducted 39-parameter phenotyping by cytometry by time of flight (CyTOF) on 33 longitudinal specimens from 11 mRNA-vaccinated individuals, of which six had previously been infected and recovered from COVID-19. // 18.10.2021

Should you get a second dose of the same vaccine if you’ve received the one-dose Johnson & Johnson shot? According to new clinical trial results published on the preprint medRxiv* server, a booster shot of a messenger RNA (mRNA) vaccine may increase your chances of neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 17.10.2021

COVID-19 vaccines remain the best tool in the pandemic toolbox against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But they are not perfect; reports have surfaced of mild to severe side effects after vaccination. A new study from researchers in the Lampe & Company GmbH & Co. KG compared the severity of adverse events from each coronavirus vaccine. // 17.10.2021

The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response. // 15.10.2021)

The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile. // 15.10.2021

U.S. health advisers said Thursday that some Americans who received Moderna’s COVID-19 vaccine at least six months ago should get a half-dose booster to rev up protection against the coronavirus. The panel of outside advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, as well as younger adults with other health problems, jobs or living situations that put them at increased risk from COVID-19. // 15.10.2021

In August, the government of India granted Emergency Use Authorization to a COVID-19 DNA vaccine. Pharmaceutical firm Zydus Cadila, in partnership with India’s Department of Biotechnology, developed the 3-dose intradermal vaccine, called ZyCov-D, which is authorized there for use in people aged 12... // 12.10.2021

Correspondence from The New England Journal of Medicine — Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines ”JnJ had lower early peak antibody compared to Pfizer and Moderna but were very stable to 8 months post vax.” //15.10.2021

A recent study seeks to investigate the characteristics of individuals with breakthrough infections post-vaccination in North Carolina, USA. // 14.10.2021

Covid-19 became the second-leading cause of death in the United States in September. // 14.10.2021

https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1?campaign_id=154&emc=edit_cb_20211013&instance_id=42791&nl=coronavirus-briefing&regi_id=168359395&segment_id=71574&te=1&user_id=7901f38baf44c98732c7fffbb9420a8d // 13.10.2021

The clinical trial studied the efficacy of Novavax’s COVID-19 vaccine, NVX-CoV2373, and found it highly effective in preventing mild, moderate, and severe COVID-19 after full vaccination. // 12.10.2021

Scientists have characterized T-cell, B-cell, and IgG responses to S antigenic sequences to evaluate vaccine effectiveness. // 13.10.2021

The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic // 12.10.2021

A new study assesses antibody and functional T-cell responses at 6 months after complete vaccination with the Pfizer-BioNTech vaccine. // 11.10.2021

A recent study demonstrates that antibodies generated in response to mRNA-based COVID-19 vaccination target more epitopes across the spike protein. // 11.10.2021

The researchers have apologized. // 10.10.2021

Waning immunity, booster shots, and maybe a restored herd immunity: What happens when a highly-vaccinated country had a big Covid wave? // 11.10.2021

Researchers have been investigating the effect that memory B cells produced in individuals who have received an mRNA vaccine have against SARS-CoV-2 variants. // 11.10.2021

Hospital admissions and deaths due to COVID-19 were drastically reduced at two weeks or more from the first dose of either the Pfizer or AstraZeneca vaccine. // 10.10.2021

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth. // 10.10.2021

The estimated incidence of myocarditis among patients that have received at least one dose of the Pfizer-BioNTech (BNT162b2) mRNA vaccine against coronavirus disease 2019 (COVID-19) was 2.13 cases per 100,000 persons, primarily affecting young men and presenting mostly as mild or moderate illness, as demonstrated by a recent study published in the New England Journal of Medicine. // 10.10.2021

The vaccine mandates have led some to question vaccine effectiveness. If the vaccines really work, they argue, then why do the vaccinated care if others choose not to get the vaccine? // 9.10.2021